超越粉样蛋白假设:利用以人为中心的复杂体外模型来解码阿尔茨海默氏病病因
Matthew Price1, Francesca Pistollato2
1School of Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
Frontiers in toxicology
|January 26, 2026
概括
以人为中心的复杂体外模型 (CIVMs) 通过复制人类大脑的复杂性来提供先进的阿尔茨海默病 (AD) 研究. 这些模型研究神经炎症和肠-大脑轴的干扰,为新的治疗点铺平了道路.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,没有有效的修改疾病的治疗方法.
- 粉样斑块假设受到新出现的证据的挑战,这些证据涉及神经炎症,感染,毒素和肠-大脑轴的破坏.
- 传统的动物和细胞模型无法完全捕捉人类AD的复杂性.
研究的目的:
- 对研究阿尔茨海默病的以人为中心的复杂体外模型 (CIVMs) 的进展进行审查.
- 评估CIVM如何用于调查AD病因学的新兴假设.
- 突出CIVM在识别新型治疗点方面的潜力.
主要方法:
- 大脑器官和器官芯片 (OOC) 技术被用作CIVMs.
- 这些模型复制了人类大脑的特征和疾病机制.
- 使用有机体和多OOC系统探索肠-大脑轴模型.
主要成果:
- CIVM成功地复制了AD的关键神经病理特征,包括血脑屏障破坏,粉样蛋白-β积累,高酸化和质激活.
- 这些模型展示了病原体或环境侮辱对神经退行症的影响.
- 早期的研究表明,微生物群衍生因素通过肠-大脑轴影响神经过程.
结论:
- 以人为中心的CIVM比AD研究的传统模型提供了更大的生理相关性.
- CIVM使得复杂的,相互关联的病理过程在AD的娱乐和机械调查.
- 这些先进的模型为识别阿尔茨海默病的因果机制和治疗点提供了新的机会.
相关概念视频
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...